These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8679062)

  • 1. Cardinal features of cognitive dysfunction in Alzheimer's disease: a factor-analytic study of the Alzheimer's Disease Assessment Scale.
    Talwalker S; Overall JE; Srirama MK; Gracon SI
    J Geriatr Psychiatry Neurol; 1996 Jan; 9(1):39-46. PubMed ID: 8679062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cardinal features of cognitive and noncognitive dysfunction and the differential efficacy of tacrine in Alzheimer's disease patients.
    Talwalker S
    J Biopharm Stat; 1996 Nov; 6(4):443-56. PubMed ID: 8969979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?
    Benge JF; Balsis S; Geraci L; Massman PJ; Doody RS
    Dement Geriatr Cogn Disord; 2009; 28(1):63-9. PubMed ID: 19641319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease.
    Doraiswamy PM; Kaiser L; Bieber F; Garman RL
    Alzheimer Dis Assoc Disord; 2001; 15(4):174-83. PubMed ID: 11723368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts.
    Cano SJ; Posner HB; Moline ML; Hurt SW; Swartz J; Hsu T; Hobart JC
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1363-8. PubMed ID: 20881017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease.
    Bilikiewicz A; Gaus W
    J Alzheimers Dis; 2004 Feb; 6(1):17-26. PubMed ID: 15004324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New scoring methodology improves the sensitivity of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials.
    Verma N; Beretvas SN; Pascual B; Masdeu JC; Markey MK;
    Alzheimers Res Ther; 2015 Nov; 7(1):64. PubMed ID: 26560146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
    Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
    Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining the reliability of ADAS-Cog change scores.
    Grochowalski JH; Liu Y; Siedlecki KL
    Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2016 Sep; 23(5):513-29. PubMed ID: 26708116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond?
    Balsis S; Benge JF; Lowe DA; Geraci L; Doody RS
    Clin Neuropsychol; 2015; 29(7):1002-9. PubMed ID: 26617181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the clinically relevant change on the ADAS-Cog?
    Schrag A; Schott JM;
    J Neurol Neurosurg Psychiatry; 2012 Feb; 83(2):171-3. PubMed ID: 22019547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The characteristics of patients with uncertain/mild cognitive impairment on the Alzheimer disease assessment scale-cognitive subscale.
    Pyo G; Elble RJ; Ala T; Markwell SJ
    Alzheimer Dis Assoc Disord; 2006; 20(1):16-22. PubMed ID: 16493231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease.
    Gillen TE; Gregg KM; Yuan H; Kurth MC; Krishnan KR
    Psychopharmacol Bull; 2001; 35(2):83-96. PubMed ID: 12397889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles.
    Le Bars PL
    Pharmacopsychiatry; 2003 Jun; 36 Suppl 1():S50-5. PubMed ID: 13130389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Validation of the Hungarian version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild cognitive impairment].
    Papp E; Pákáski M; Drótos G; Kálmán J
    Psychiatr Hung; 2012; 27(6):426-34. PubMed ID: 23429337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
    Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the utility of everyday memory test and the Alzheimer's Disease Assessment Scale-Cognitive part for evaluation of mild cognitive impairment and very mild Alzheimer's disease.
    Adachi H; Shinagawa S; Komori K; Toyota Y; Mori T; Matsumoto T; Sonobe N; Kashibayashi T; Ishikawa T; Fukuhara R; Ikeda M
    Psychiatry Clin Neurosci; 2013 Apr; 67(3):148-53. PubMed ID: 23581865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale)--validation of the Slovak version.
    Kolibas E; Korinkova V; Novotny V; Vajdickova K; Hunakova D
    Bratisl Lek Listy; 2000; 101(11):598-602. PubMed ID: 11218956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.